Skip to content

PressReach

SEARCH icon
  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos

PressReach

icon

      HomeNASDAQ:GILD

      NASDAQ:GILD

      Is GILD Stock a Buy Near 52-Week Lows for Its 4% Yield?
      Investing News

      Is GILD Stock a Buy Near 52-Week Lows for Its 4% Yield?

      February 21, 2024
      Gilead Trodelvy Has Shown Promise in Breast Cancer Patients’ Clinical Trials, Regardless of HER2 Mutation
      Investing News

      Gilead Trodelvy Has Shown Promise in Breast Cancer Patients’ Clinical Trials, Regardless of HER2 Mutation

      September 5, 2022
      3 Healthcare Equities That May Benefit From Senate Democrats’ $21 Billion Proposal in New COVID-19 Funding
      Investing News

      3 Healthcare Equities That May Benefit From Senate Democrats’ $21 Billion Proposal in New COVID-19 Funding

      August 4, 2022

       

      LATEST NEWS

      • Investing News Beta Technologies Q3 IPO Insights
      • Investing News Salesforce Reports Robust Q3 2026 Earnings
      • Investing News Salesforce’s Stock Boost Amid Raised Guidance
      • Investing News Macy’s Q3 2025 Earnings Overview
      • Investing News Okta’s Strong Q3 2026 Earnings Boost Shares

      PressReach

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from PressReach.

      I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

      Market Jar Media Inc. © 2025